Updated results of PEANUT trial: Pembrolizumab and nabpaclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

被引：0
|
作者：
Bottiglieri, A. [1 ]
Bravo, W. Ferrari [1 ]
Rametta, A. [1 ]
Provenzano, L. [1 ]
Raggi, D. [2 ]
Marandino, L. [2 ]
Fare, E. [3 ]
Longo, V. [1 ]
Guadalupi, V. [1 ]
Stellato, M. [1 ]
Verzoni, E. [1 ]
Sepe, P. [1 ]
Claps, M. [1 ]
Calareso, G. [4 ]
Alessi, A. [5 ]
Cattaneo, L. [6 ]
Colecchia, M. [7 ]
Procopio, G. [1 ]
Necchi, A. [2 ]
Giannatempo, P. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[2] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy
[3] Osped Civile Legnano, Dept Med Oncol, Legnano, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Intervent Radiol, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Dept Nucl Med, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Adv Diagnost Dept, Milan, Italy
[7] IRCCS Osped San Raffaele, Dept Pathol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2370P
引用
收藏
页码：S1206 / S1206
页数：1
相关论文
共 50 条
  • [31] Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma
    Sonpavde, Guru
    Bellmunt, Joaquim
    Rosenberg, Jonathon E.
    Regazzi, Ashley M.
    Bajorin, Dean F.
    Choueiri, Toni K.
    Qu, Angela Q.
    Niegisch, Guenter
    Albers, Peter
    Necchi, Andrea
    Di Lorenzo, Giuseppe
    Fougeray, Ronan
    Wong, Yu-Ning
    Sridhar, Srikala S.
    Ko, Yoo-Joung
    Milowsky, Matthew I.
    Galsky, Matthew D.
    Pond, Gregory R.
    CLINICAL GENITOURINARY CANCER, 2014, 12 (06) : 395 - 398
  • [32] Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC).
    Loriot, Yohann
    Balar, Arjun Vasant
    Dreicer, Robert
    Hoffman-Censits, Jean H.
    Perez-Gracia, Jose Luis
    Petrylak, Daniel Peter
    Van der Heijden, Michiel Simon
    Shen, Xiaodong
    Zhu, Qian
    Ding, Beiying
    Kaiser, Constanze
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Stecca, Carlos
    Selvarajah, Shamini
    Jiang, Di Maria
    Abdeljalil, Osama
    Zhang, Tong
    Bedard, Philippe L.
    Hansen, Aaron Richard
    Fallah-Rad, Nazanin
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
    Ye, Dingwei
    Liu, Jiyan
    Zhou, Aiping
    Zou, Qing
    Li, Hanzhong
    Fu, Cheng
    Hu, Hailong
    Huang, Jian
    Zhu, Shaoxing
    Jin, Jie
    Ma, Lulin
    Guo, Jianming
    Xiao, Jun
    Park, Se Hoon
    Zhang, Dahong
    Qiu, Xiusong
    Bao, Yuanyuan
    Zhang, Lilin
    Shen, Wei
    Bi, Feng
    CANCER SCIENCE, 2021, 112 (01) : 305 - 313
  • [35] Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
    van der Heijden, Michiel S.
    Loriot, Yohann
    Duran, Ignacio
    Ravaud, Alain
    Retz, Margitta
    Vogelzang, Nicholas J.
    Nelson, Betty
    Wang, Jingjing
    Shen, Xiaodong
    Powles, Thomas
    EUROPEAN UROLOGY, 2021, 80 (01) : 7 - 11
  • [36] Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
    Fontes, Mariane S.
    de Almeida, Daniel Vargas Pivato
    Cavalin, Clarissa
    Tagawa, Scott T.
    ONCOTARGETS AND THERAPY, 2022, 15 : 1531 - 1542
  • [37] Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a targeted literature review (TLR).
    Kearney, Mairead
    Janssens, Rosanne
    Quaife, Matt
    Trapali, Myrto
    Thomas, Caitlin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [38] Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Rosenberg, Jonathan E.
    Flaig, Thomas W.
    Friedlander, Terence W.
    Milowsky, Matthew I.
    Srinivas, Sandy
    Petrylak, Daniel Peter
    Merchan, Jaime R.
    Bilen, Mehmet Asim
    Carret, Anne-Sophie
    Yuan, Nancy
    Sasse, Carolyn
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
    Li, Siming
    Shi, Yanxia
    Dong, Haiying
    Guo, Hongqian
    Xie, Yu
    Sun, Zhongquan
    Zhang, Xiaoping
    Kim, Eric
    Zhang, Jun
    Li, Yue
    Xu, Chenming
    Kadeerbai, Haishan
    Lee, Sue
    Gorla, Seema
    Guo, Jun
    Sheng, Xinan
    CANCER MEDICINE, 2024, 13 (21):
  • [40] Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
    Rosenberg, Jonathan E.
    Flaig, Thomas W.
    Friedlander, Terence W.
    Milowsky, Matthew, I
    Srinivas, Sandy
    Petrylak, Daniel Peter
    Merchan, Jaime R.
    Bilen, Mehmet Asim
    Carret, Anne-Sophie
    Yuan, Nancy
    Sasse, Carolyn
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345